United States Biotechnology & Medical Research

Keros Therapeutics Inc (KROS)

Track

Track

Keros Therapeutics witnessed ten insider trading transactions over the past ninety days. Executives and directors executed sales totaling $117,849.51, while purchases reached $31,070.00. These activities follow a recent earnings report showing a sixteen percent shortfall. The stock price has risen 11.1% during this period, reflecting ongoing market volatility for the healthcare firm.
Ticker: KROS Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Keros Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.5
Newton Charles W. Non-Executive Director
Transaction date
Planned sale
Price
373.04
Quantity 77,787 -34.3%
Value US$3,178,203
Tanini Annita Corp. Controller & VP, Finance Officer
Transaction date
Sale
Price
98.18
Quantity 51,897 -8.3%
Value US$1,958,237
3.3
Lerner Lorena Raquel Chief Scientific Officer Officer
Transaction date
Sale
Price
213.43
Quantity 38,785 -27.7%
Value US$1,772,290
Cho Esther Chief Legal Officer Officer
Transaction date
Planned sale
Price
10.29
Quantity 1,000 -11.1%
Value US$100,000
1.5
Newton Charles W. Director Non-Executive Director
Transaction date
Proposed sale
Price
10.38
Quantity 1,000
Value US$100,000
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Planned purchase
Price
10.27
Quantity 1,000 +5.4%
Value US$100,000
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Planned purchase
Price
10.61
Quantity 1,000 +5.7%
Value US$10,610
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Planned purchase
Price
10.19
Quantity 1,000 +6.0%
Value US$10,190
1.5
Newton Charles W. Non-Executive Director
Transaction date
Planned sale
Price
10.04
Quantity 550 -4.2%
Value US$5,522
1.5
Newton Charles W. Director Non-Executive Director
Transaction date
Proposed sale
Price
9.95
Quantity 550
Value US$5,472
Farzan Nima Non-Executive Director
Transaction date
Planned sale
Price
10.73
Quantity 2,625 -21.2%
Value US$28,166
3.3
Knowles Julius Non-Executive Director
Transaction date
Planned sale
Price
10.73
Quantity 2,625 -19.3%
Value US$28,166
1.3
Seth Alpna Non-Executive Director
Transaction date
Planned sale
Price
10.72
Quantity 2,625 -21.2%
Value US$28,140
Farzan Nima Director Non-Executive Director
Transaction date
Proposed sale
Price
10.68
Quantity 2,625
Value US$28,035
1.3
Seth Alpna Director Non-Executive Director
Transaction date
Proposed sale
Price
10.68
Quantity 2,625
Value US$28,035
3.3
Knowles Julius Director Non-Executive Director
Transaction date
Proposed sale
Price
10.68
Quantity 2,625
Value US$28,035
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Planned purchase
Price
10.58
Quantity 1,000 +11.8%
Value US$10,580
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Planned purchase
Price
11.70
Quantity 1,000 +13.4%
Value US$11,700
2.6
OrbiMed Genesis Master Fund, LP Shareholder; Director Non-Executive Director
Transaction date
Proposed sale
Price
11.04
Quantity 45,057
Value US$497,429
2.9
BIENAIME JEAN JACQUES Non-Executive Director
Transaction date
Planned purchase
Price
11.21
Quantity 2,000 +36.7%
Value US$22,420
3.3
Seehra Jasbir CHIEF EXECUTIVE OFFICER Executive Director
Transaction date
Sale
Price
16.17
Quantity 7,015 -1.8%
Value US$113,433
3.3
Lerner Lorena Raquel Chief Science Officer Officer
Transaction date
Sale
Price
16.35
Quantity 3,873 -11.1%
Value US$63,324
3.3
Regnante Keith CHIEF FINANCIAL OFFICER Officer
Transaction date
Sale
Price
16.35
Quantity 4,739 -10.8%
Value US$77,483
Cho Esther SVP, General Counsel Officer
Transaction date
Planned sale
Price
16.35
Quantity 4,745 -10.7%
Value US$77,581
Rovaldi Christopher Affiliate
Transaction date
Proposed sale
Price
15.71
Quantity 85,306
Value US$1,340,157
1.5
GORDON CARL L Non-Executive Director
Transaction date
Sale
Price
44.01
Quantity 29,400 -19.7%
Value US$1,293,894
1.5
GORDON CARL L Non-Executive Director
Transaction date
Sale
Price
44.01
Quantity 220,600 -19.7%
Value US$9,708,606
2.6
ORBIMED ADVISORS LLC Non-Executive Director
Transaction date
Sale
Price
44.01
Quantity 29,400 -19.7%
Value US$1,293,894
2.6
ORBIMED ADVISORS LLC Non-Executive Director
Transaction date
Sale
Price
44.01
Quantity 220,600 -19.7%
Value US$9,708,606
2.6
OrbiMed Genesis Master Fund, LP Shareholder; Director Non-Executive Director
Transaction date
Proposed sale
Price
44.84
Quantity 29,400
Value US$1,318,296
3.3
Regnante Keith Officer Officer
Transaction date
Proposed sale
Price
45.29
Quantity 40,000
Value US$1,811,600
3.3
Regnante Keith Chief Financial Officer Officer
Transaction date
Planned sale
Price
45.29
Quantity 40,000 -100.0%
Value US$1,811,600
3.3
Regnante Keith Chief Financial Officer Officer
Transaction date
Planned sale
Price
47.25
Quantity 2,579 -100.0%
Value US$121,858
3.3
Regnante Keith Chief Financial Officer Officer
Transaction date
Planned sale
Price
46.46
Quantity 1,428 -35.6%
Value US$66,345
3.3
Regnante Keith Chief Financial Officer Officer
Transaction date
Planned sale
Price
45.03
Quantity 15,993 -80.0%
Value US$720,165
3.3
Regnante Keith Officer Officer
Transaction date
Proposed sale
Price
45.42
Quantity 20,000
Value US$908,322
3.3
Regnante Keith Chief Financial Officer Officer
Transaction date
Planned sale
Price
48.65
Quantity 2,699 -100.0%
Value US$131,306
3.3
Regnante Keith Chief Financial Officer Officer
Transaction date
Planned sale
Price
47.66
Quantity 17,301 -86.5%
Value US$824,566
3.3
Regnante Keith Officer Officer
Transaction date
Proposed sale
Price
47.79
Quantity 20,000
Value US$955,852
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.00
Quantity 46,034 -32.6%
Value US$1,381,020
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.00
Quantity 1,916 -2.0%
Value US$57,480
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
45.45
Quantity 16 -0.0%
Value US$727
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
44.23
Quantity 223 -0.3%
Value US$9,863
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
43.32
Quantity 719 -0.8%
Value US$31,147
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
42.49
Quantity 944 -1.1%
Value US$40,111
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
41.26
Quantity 3,398 -3.7%
Value US$140,201
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
64.15
Quantity 559 -0.6%
Value US$35,860
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
63.50
Quantity 2,315 -2.6%
Value US$147,002
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
62.32
Quantity 1,009 -1.1%
Value US$62,881
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
61.37
Quantity 1,417 -1.6%
Value US$86,961
Rovaldi Christopher Chief Operating Officer Officer
Transaction date
Planned sale
Price
65.00
Quantity 1,728 -100.0%
Value US$112,320
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
60.00
Quantity 7,950 -8.5%
Value US$477,000
Rovaldi Christopher Chief Operating Officer Officer
Transaction date
Planned sale
Price
58.83
Quantity 105 -100.0%
Value US$6,177
Rovaldi Christopher Chief Operating Officer Officer
Transaction date
Planned sale
Price
57.97
Quantity 366 -77.7%
Value US$21,217
Rovaldi Christopher Chief Operating Officer Officer
Transaction date
Planned sale
Price
56.89
Quantity 287 -37.9%
Value US$16,327
Rovaldi Christopher Chief Operating Officer Officer
Transaction date
Planned sale
Price
56.20
Quantity 104 -12.1%
Value US$5,845
Rovaldi Christopher Chief Operating Officer Officer
Transaction date
Planned sale
Price
54.34
Quantity 2 -0.2%
Value US$109
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
54.54
Quantity 875 -1.0%
Value US$47,722
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
53.36
Quantity 713 -0.8%
Value US$38,046
Lachey Jennifer Chief Scientific Officer Officer
Transaction date
Planned sale
Price
52.43
Quantity 1,062 -1.2%
Value US$55,681
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-20 2026-08-18 PlS Planned sale
1.5
Newton Charles W.
Non-Executive Director
77,787 -34.3%
373.04
US$3,178,203 		77,787 -34.3% 373.04 US$3,178,203
2026-08-20 2026-08-18 S Sale
Tanini Annita

Corp. Controller & VP, Finance

Officer
51,897 -8.3%
98.18
US$1,958,237 		51,897 -8.3% 98.18 US$1,958,237
2026-08-20 2026-08-18 S Sale
3.3
Lerner Lorena Raquel

Chief Scientific Officer

Officer
38,785 -27.7%
213.43
US$1,772,290 		38,785 -27.7% 213.43 US$1,772,290
2026-08-20 2026-08-18 PlS Planned sale
Cho Esther

Chief Legal Officer

Officer
1,000 -11.1%
10.29
US$100,000 		1,000 -11.1% 10.29 US$100,000
2026-08-18 2026-08-18 PrS Proposed sale
1.5
Newton Charles W.

Director

Non-Executive Director
1,000
10.38
US$100,000 		1,000 10.38 US$100,000
2026-08-19 2026-08-17 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +5.4%
10.27
US$100,000 		1,000 +5.4% 10.27 US$100,000
2026-07-17 2026-07-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +5.7%
10.61
US$10,610 		1,000 +5.7% 10.61 US$10,610
2026-06-17 2026-06-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +6.0%
10.19
US$10,190 		1,000 +6.0% 10.19 US$10,190
2026-06-15 2026-06-11 PlS Planned sale
1.5
Newton Charles W.
Non-Executive Director
550 -4.2%
10.04
US$5,522 		550 -4.2% 10.04 US$5,522
2026-06-11 2026-06-11 PrS Proposed sale
1.5
Newton Charles W.

Director

Non-Executive Director
550
9.95
US$5,472 		550 9.95 US$5,472
2026-06-08 2026-06-04 PlS Planned sale
Farzan Nima
Non-Executive Director
2,625 -21.2%
10.73
US$28,166 		2,625 -21.2% 10.73 US$28,166
2026-06-08 2026-06-04 PlS Planned sale
3.3
Knowles Julius
Non-Executive Director
2,625 -19.3%
10.73
US$28,166 		2,625 -19.3% 10.73 US$28,166
2026-06-05 2026-06-04 PlS Planned sale
1.3
Seth Alpna
Non-Executive Director
2,625 -21.2%
10.72
US$28,140 		2,625 -21.2% 10.72 US$28,140
2026-06-04 2026-06-04 PrS Proposed sale
Farzan Nima

Director

Non-Executive Director
2,625
10.68
US$28,035 		2,625 10.68 US$28,035
2026-06-04 2026-06-04 PrS Proposed sale
1.3
Seth Alpna

Director

Non-Executive Director
2,625
10.68
US$28,035 		2,625 10.68 US$28,035
2026-06-04 2026-06-04 PrS Proposed sale
3.3
Knowles Julius

Director

Non-Executive Director
2,625
10.68
US$28,035 		2,625 10.68 US$28,035
2026-05-19 2026-05-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +11.8%
10.58
US$10,580 		1,000 +11.8% 10.58 US$10,580
2026-04-17 2026-04-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +13.4%
11.70
US$11,700 		1,000 +13.4% 11.70 US$11,700
2026-03-31 2026-03-31 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, LP

Shareholder; Director

Non-Executive Director
45,057
11.04
US$497,429 		45,057 11.04 US$497,429
2026-03-11 2026-03-09 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
2,000 +36.7%
11.21
US$22,420 		2,000 +36.7% 11.21 US$22,420
2026-02-20 2026-02-19 S Sale
3.3
Seehra Jasbir

CHIEF EXECUTIVE OFFICER

Executive Director
7,015 -1.8%
16.17
US$113,433 		7,015 -1.8% 16.17 US$113,433
2026-02-20 2026-02-18 S Sale
3.3
Lerner Lorena Raquel

Chief Science Officer

Officer
3,873 -11.1%
16.35
US$63,324 		3,873 -11.1% 16.35 US$63,324
2026-02-20 2026-02-18 S Sale
3.3
Regnante Keith

CHIEF FINANCIAL OFFICER

Officer
4,739 -10.8%
16.35
US$77,483 		4,739 -10.8% 16.35 US$77,483
2026-02-20 2026-02-18 PlS Planned sale
Cho Esther

SVP, General Counsel

Officer
4,745 -10.7%
16.35
US$77,581 		4,745 -10.7% 16.35 US$77,581
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
155,262 -100.0%
17.75
US$2,755,900 		155,262 -100.0% 17.75 US$2,755,900
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
1,226,412 -100.0%
17.75
US$21,768,813 		1,226,412 -100.0% 17.75 US$21,768,813
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
1,121,045 -100.0%
17.75
US$19,898,549 		1,121,045 -100.0% 17.75 US$19,898,549
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
2,284,612 -100.0%
17.75
US$40,551,863 		2,284,612 -100.0% 17.75 US$40,551,863
2025-10-15 2025-10-15 S Sale
4.0
ADAR1 Capital Management, LLC
Large shareholder
743,358 -100.0%
17.75
US$13,194,604 		743,358 -100.0% 17.75 US$13,194,604
2025-10-15 2025-10-15 S Sale
4.0
ADAR1 Capital Management, LLC
Large shareholder
254,669 -100.0%
17.75
US$4,520,375 		254,669 -100.0% 17.75 US$4,520,375
2025-10-15 2025-10-15 S Sale
4.0
ADAR1 Capital Management, LLC
Large shareholder
4,391,237 -100.0%
17.75
US$77,944,457 		4,391,237 -100.0% 17.75 US$77,944,457
2025-09-12 2025-09-12 PrS Proposed sale
Rovaldi Christopher

Affiliate
85,306
15.71
US$1,340,157 		85,306 15.71 US$1,340,157
2025-04-11 2025-04-09 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
74,333 +1.7%
10.33
US$767,860 		74,333 +1.7% 10.33 US$767,860
2025-04-11 2025-04-09 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
500,000 +13.1%
10.33
US$5,165,000 		500,000 +13.1% 10.33 US$5,165,000
2025-04-11 2025-04-09 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
325,000 +9.3%
9.86
US$3,203,525 		325,000 +9.3% 9.86 US$3,203,525
2025-04-11 2025-04-09 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
16,365 +2.3%
9.40
US$153,752 		16,365 +2.3% 9.40 US$153,752
2025-04-11 2025-04-09 B Purchase
4.0
ADAR1 Capital Management, LLC
Large shareholder
18,560 +0.5%
9.40
US$174,375 		18,560 +0.5% 9.40 US$174,375
2024-08-15 2024-08-13 S Sale
1.5
GORDON CARL L
Non-Executive Director
29,400 -19.7%
44.01
US$1,293,894 		29,400 -19.7% 44.01 US$1,293,894
2024-08-15 2024-08-13 S Sale
1.5
GORDON CARL L
Non-Executive Director
220,600 -19.7%
44.01
US$9,708,606 		220,600 -19.7% 44.01 US$9,708,606
2024-08-15 2024-08-13 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
29,400 -19.7%
44.01
US$1,293,894 		29,400 -19.7% 44.01 US$1,293,894
2024-08-15 2024-08-13 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
220,600 -19.7%
44.01
US$9,708,606 		220,600 -19.7% 44.01 US$9,708,606
2024-08-13 2024-08-13 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, LP

Shareholder; Director

Non-Executive Director
29,400
44.84
US$1,318,296 		29,400 44.84 US$1,318,296
2024-08-13 2024-08-13 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder; Director

Non-Executive Director
220,600
44.84
US$9,891,704 		220,600 44.84 US$9,891,704
2024-01-04 2024-01-04 PrS Proposed sale
3.3
Regnante Keith

Officer

Officer
40,000
45.29
US$1,811,600 		40,000 45.29 US$1,811,600
2023-12-11 2023-12-11 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
246,000
35.65
US$8,769,900 		246,000 35.65 US$8,769,900
2024-01-08 2023-11-04 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
40,000 -100.0%
45.29
US$1,811,600 		40,000 -100.0% 45.29 US$1,811,600
2023-06-12 2023-06-12 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
170,000
43.89
US$7,461,300 		170,000 43.89 US$7,461,300
2023-06-12 2023-06-09 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
2,579 -100.0%
47.25
US$121,858 		2,579 -100.0% 47.25 US$121,858
2023-06-12 2023-06-09 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
1,428 -35.6%
46.46
US$66,345 		1,428 -35.6% 46.46 US$66,345
2023-06-12 2023-06-09 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
15,993 -80.0%
45.03
US$720,165 		15,993 -80.0% 45.03 US$720,165
2023-06-09 2023-06-09 PrS Proposed sale
3.3
Regnante Keith

Officer

Officer
20,000
45.42
US$908,322 		20,000 45.42 US$908,322
2023-06-12 2023-06-08 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
2,699 -100.0%
48.65
US$131,306 		2,699 -100.0% 48.65 US$131,306
2023-06-12 2023-06-08 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
17,301 -86.5%
47.66
US$824,566 		17,301 -86.5% 47.66 US$824,566
2023-06-08 2023-06-08 PrS Proposed sale
3.3
Regnante Keith

Officer

Officer
20,000
47.79
US$955,852 		20,000 47.79 US$955,852
2022-07-19 2022-07-15 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
46,034 -32.6%
30.00
US$1,381,020 		46,034 -32.6% 30.00 US$1,381,020
2022-07-15 2022-07-13 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,916 -2.0%
30.00
US$57,480 		1,916 -2.0% 30.00 US$57,480
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
16 -0.0%
45.45
US$727 		16 -0.0% 45.45 US$727
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
223 -0.3%
44.23
US$9,863 		223 -0.3% 44.23 US$9,863
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
719 -0.8%
43.32
US$31,147 		719 -0.8% 43.32 US$31,147
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
944 -1.1%
42.49
US$40,111 		944 -1.1% 42.49 US$40,111
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
3,398 -3.7%
41.26
US$140,201 		3,398 -3.7% 41.26 US$140,201
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
559 -0.6%
64.15
US$35,860 		559 -0.6% 64.15 US$35,860
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
2,315 -2.6%
63.50
US$147,002 		2,315 -2.6% 63.50 US$147,002
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,009 -1.1%
62.32
US$62,881 		1,009 -1.1% 62.32 US$62,881
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,417 -1.6%
61.37
US$86,961 		1,417 -1.6% 61.37 US$86,961
2022-04-08 2022-04-06 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
1,728 -100.0%
65.00
US$112,320 		1,728 -100.0% 65.00 US$112,320
2022-04-06 2022-04-04 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
7,950 -8.5%
60.00
US$477,000 		7,950 -8.5% 60.00 US$477,000
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
105 -100.0%
58.83
US$6,177 		105 -100.0% 58.83 US$6,177
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
366 -77.7%
57.97
US$21,217 		366 -77.7% 57.97 US$21,217
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
287 -37.9%
56.89
US$16,327 		287 -37.9% 56.89 US$16,327
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
104 -12.1%
56.20
US$5,845 		104 -12.1% 56.20 US$5,845
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
2 -0.2%
54.34
US$109 		2 -0.2% 54.34 US$109
2022-03-15 2022-03-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
875 -1.0%
54.54
US$47,722 		875 -1.0% 54.54 US$47,722
2022-03-15 2022-03-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
713 -0.8%
53.36
US$38,046 		713 -0.8% 53.36 US$38,046
2022-03-15 2022-03-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,062 -1.2%
52.43
US$55,681 		1,062 -1.2% 52.43 US$55,681
Explore more

More insider trading research around Keros Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America